Transpharmation Collaborates With Artelo Biosciences To Support Development Of Neuropathic Pain Treatment

Transpharmation is delighted to have worked with Artelo Biosciences, Inc. to support development of the FABP5 inhibitor ART26.12 as a neuropathic pain treatment. Using behavioural outcomes in animal models induced by paclitaxel and streptozotocin, we have validated the analgesic efficacy of ART26.12 in chemotherapy and diabetes-induced neuropathies, respectively. Evidencing these positive effects in these clinically relevant models of Neuropathic Pain was revealed at the recent 33rd Annual International Cannabinoid Research Society Symposium in Toronto, Canada. For further information on our preclinical pain models contact Christopher Tsantoulas, Principal Scientist.